Cargando…

Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants

BACKGROUND: Patients with non-valvular atrial fibrillation (NVAF) need prophylactically antithrombotic therapies to reduce the risk of stroke. We hypothesized that the prognostic benefits of prophylactic antithrombotic therapies outweighed the bleeding risk among very elderly (≥85 years old) patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	O, U Fan, Chong, Tou Kun, Wei, Yulin, Paudel, Bishow, Giudici, Michael C., Wong, Chi Wa, Lei, Wai Kit, Chen, Jian, Wu, Wei, Liu, Kan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968574/ https://www.ncbi.nlm.nih.gov/pubmed/35372665 http://dx.doi.org/10.1016/j.ijcha.2022.101009

Ejemplares similares

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation
por: O, U Fan, et al.
Publicado: (2022)

Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
por: Yamato, Hiroshi, et al.
Publicado: (2020)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non‐valvular atrial fibrillation (cognitive decline and dementia in patients with non‐valvular atrial fibrillation [CAF] trial)
por: Bunch, Thomas Jared, et al.
Publicado: (2022)

Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation
por: Yavasoglu, Nese G., et al.
Publicado: (2021)

Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
por: Botto, Gianluca, et al.
Publicado: (2021)

RWD82 Influence of the COVID-19 Pandemic on Patients Receiving Oral Anticoagulants for the Treatment of Non-Valvular Atrial Fibrillation
por: Comin-Colet, J, et al.
Publicado: (2022)

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
por: Di Biase, Luigi
Publicado: (2016)

Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls
por: Shanah, Layla, et al.
Publicado: (2020)

Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation
por: Song, Ting, et al.
Publicado: (2021)

Editorial to “The differences of atrial thrombus locations and variable response to anticoagulation in non‐valvular atrial fibrillation with ventricular cardiomyopathy”
por: Chung, Wei‐Hsin, et al.
Publicado: (2020)

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Erratum to: The Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)

Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients
por: Öncel, Can Ramazan
Publicado: (2016)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

Management and Anticoagulation Treatment of Non-Valvular Atrial Fibrillation in Elderly Patients: The Dali Study
por: Huang, Hong, et al.
Publicado: (2023)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
por: Umei, Masahiko, et al.
Publicado: (2017)

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
por: Amin, Alpesh, et al.
Publicado: (2019)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study
por: Montomoli, Marco, et al.
Publicado: (2022)

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
por: Dhamane, Amol D., et al.
Publicado: (2022)

Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation
por: Atwater, Brett D., et al.
Publicado: (2023)

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)

Comparison Between Oral Anticoagulation and Left Atrial Appendage Occlusion in the Prevention of Stroke With Regard to Non-Valvular Atrial Fibrillation
por: Sandhu, Osama, et al.
Publicado: (2020)

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
por: Liu, Feng-Di, et al.
Publicado: (2016)

Relationship between valvular structure and biochemical indices of non-valvular atrial fibrillation and senile degenerative valvular heart disease
por: Chen, Jian-Qin, et al.
Publicado: (2023)

Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery
por: Park, Bo Eun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nbgvvpf5f8cvlgsu4568fl20r9